AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05364671
Drug: Raphamin
RxNorm normalized name: Allantoin 0.007 g in 0.7 g TOPICAL POWDER [RAPHAGEN POWDE R]
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. On the first day, 8 tablets should be administered using the following regimen: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), then additionally one tablet 3 times with regular time intervals. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 5 days.
Trial: NCT05317611
Drug: Intraperitoneal instillation of ondansetron and bupivacaine
RxNorm normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The aim is to detect the effect of intraperitoneal instillation of ondansetron for prevention of postoperative nausea and vomiting
Trial: NCT05317611
Drug: Intravenous ondansetron and intraperitoneal instillation of bupivacaine
RxNorm normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The aim is to detect effect of intravenous ondansetron for prevention of postoperative nausea and vomiting
Trial: NCT05317611
Drug: Intraperitoneal instillation of bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The aim is to detect effect of intraperitoneal instillation of bupivacaine
Trial: NCT05775965
Drug: Rivaroxaban 10mg
RxNorm normalized name: RIVAROXABAN 10MG TAB
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 10mg daily for 35 days post hip fracture surgery
Trial: NCT04941781
Drug: PIPE-307
RxNorm normalized name: Horse-pipes Top
DrugBank: Equisetum arvense top (DB14349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with \[11C\] PIPE-307.~Subjects will receive an intravenous dose of the radioligand \[11C\] PIPE-307 prior to PET imaging.
Trial: NCT04905251
Drug: Mifepristone-Misoprostol
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non interventional design.
Trial: NCT05358535
Drug: Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab.
Trial: NCT05358535
Drug: Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab.
Trial: NCT04795726
Drug: Finerenone (BAY94-8862)
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
Trial: NCT06770530
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg inravenous Fluconazole, single dose 200 ml
Trial: NCT05058560
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tislelizumab, 200 mg IV Q3W, up to one year.
Trial: NCT06765993
Drug: Isosorbide oral solution
RxNorm normalized name: Isosorbide Oral Solution
DrugBank: Isosorbide (DB09401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mL, TID
Trial: NCT05732428
Drug: ARV-471
RxNorm normalized name: Arv-110 (protac)
DrugBank: Bavdegalutamide (DB19032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARV-471 will be administered orally once daily with food (eg, a light meal of approximately 400 to 600 calories which includes a mixture of fat carbohydrates, and protein) at RP3D for monotherapy defined in study ARV-471-mBC-101, in continuous dosing over 28-day cycles
Trial: NCT05057845
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab will be initiated on day 14 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks
Trial: NCT05057845
Drug: lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Trial: NCT06773962
Drug: TB006
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion.
Trial: NCT05619913
Drug: Eribulin Mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesilate is a first-in-class halichondrin B-based, microtubule dynamics inhibitor7. It inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into non-productive aggregates.
Trial: NCT05619913
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
Trial: NCT05156710
Drug: Intravenous immunoglobulin (IVIg)
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Trial: NCT05156710
Drug: Rituximab or biosimilar
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Trial: NCT05156710
Drug: Antithymocyte globulin (ATG)
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Trial: NCT05156710
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical Form: Tablet Route of Administration: Oral
Trial: NCT05156710
Drug: Mycophenolate
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical Form: Tablet Route of Administration: Oral
Trial: NCT04835805
Drug: Belvarafenib
RxNorm normalized name: Belvarafenib
DrugBank: Belvarafenib (DB17568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily (BID), continuous dosing
Trial: NCT04835805
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off
Trial: NCT04835805
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once every 4 weeks (Q4W)
Trial: NCT05720949
Drug: Genicular Nerve Block with bupivacaine and preservative free dexamethasone
RxNorm normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A genicular nerve block is a peripheral nerve block that temporarily anesthetizes the sensory terminal branches innervating the knee joint by injecting local anesthesia. This results in anesthesia of the anterior compartment of the knee.~The genicular nerve block consists of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone and will be applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius.~Bupivacaine - Drug class: Sodium channel blocker~Dexamethasone - Drug class: Glucocorticoid
Trial: NCT06316856
Drug: Autologous CD5 CAR T-cells
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.
Trial: NCT06316856
Drug: Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells
RxNorm normalized name: Bone-marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.
Trial: NCT06316856
Drug: Newly matched donor-derived CD5 CAR T-cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
Trial: NCT04881032
Drug: Polysiloxane Gd-Chelates based nanoparticles (AGuIX)
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four intravenous injections of AGuIX will be delivered. Phase I : Three dose levels may be explored 50 mg/kg, 75 mg/kg and 100 mg/ kg. Phase II : recommended dose
Trial: NCT04881032
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concomitant chemotherapy consists of temozolomide (TMZ) at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy.~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days .
Trial: NCT06013020
Drug: NOAC+DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Century Clot-guided rivaroxaban plus DAPT.
Trial: NCT06013020
Drug: DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard DAPT for 1 month, following lower-dose ticagrelor or clopidogrel plus aspirin for 11 months.
Trial: NCT04963270
Drug: Satralizumab
RxNorm normalized name: SATRALIZUMAB
DrugBank: Satralizumab (DB15762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Satralizumab will be administered as a subcutaneous injection
Trial: NCT06263673
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg once daily, oral
Trial: NCT06263673
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg once daily, oral
Trial: NCT06450210
Drug: psilocybin trihydrate
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdoses of psilocybin trihydrate will be administered to participants (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg).
Trial: NCT06520345
Drug: 177Lu-TLX591
RxNorm normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to Group A will receive two 76 mCi (±10%) doses of 177Lu-TLX591 14 days apart
Trial: NCT06520345
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.
Trial: NCT06520345
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)
Trial: NCT06520345
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles
Trial: NCT05269017
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Devarol S amp containing 200,000 units per 2 ml giving a concentration of 5,000 units per drops for four weeks
Trial: NCT05269017
Drug: Budesonide nasal spray
RxNorm normalized name: Budesonide Nasal Spray
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 64 µg per puff in a dose of 1 puff for each nostril twice daily for four weeks
Trial: NCT06087536
Drug: OMN6
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort 1: 50 mg x 3/day Cohort 2: 100 mg x 3/day Cohort 3: 150 mg x 3/day~3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days
Trial: NCT06530290
Drug: Mirtazapine 15 MG
RxNorm normalized name: mirtazapine 15 MG
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine (15 mg), once a day for 12 weeks
Trial: NCT05759156
Drug: Tranexamic acid injection
RxNorm normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention consists of administration of 1gm of Tranexamic acid (TXA) intravenously or 10-mls of placebo (normal saline) intravenously, slowly over 30-60 sec, within 3 mins of the delivery of baby.
Trial: NCT06454188
Drug: Upadacitinib 15 MG [Rinvoq]
RxNorm normalized name: upadacitinib 15 MG [Rinvoq]
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg tablet once per day.
Trial: NCT05730816
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
Trial: NCT05426252
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept, co-stimulation blockade, to be given for GVHD prophylaxis in combination with sirolimus post allogeneic hematopoietic stem cell transplantation.
Trial: NCT05426252
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus, mTOR inhibitor, to be given for GVHD prophylaxis in combination with abatacept post allogeneic hematopoietic stem cell transplantation.
Trial: NCT04593680
Drug: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first full PK measurement of MHT will be performed starting at week 4 and end at week 6 to assess the steady-state plasma PK of testosterone in the absence of PrEP. The second PK measurement of MHT will be performed starting at week 12 and end at week 14 to assess plasma PK of testosterone in the presence of both MHT and PrEP. The first full PK measurement of PrEP will be performed at week 12 to assess the steady-state plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the presence of both MHT and PrEP. The second measurement of PrEP will be performed at week 16 to assess plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the absence of MHT.
Trial: NCT06235801
Drug: Gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT06235801
Drug: Momelotinib
RxNorm normalized name: MOMELOTINIB
DrugBank: Momelotinib (DB11763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06639503
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mL 0.25% bupivacain
Trial: NCT04722848
Drug: Ponatinib + Blinatumomab
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients aged 18-65 will receive Ponatinib at the dose of 45 mg/day for the first 22 days and then will reduce the dose to 30 mg (depending on the morphologic and molecular response), whereas patients older than 65 years will start Ponatinib at 30 mg/day, in order to avoid TAEs. Patients will continue treatment with Ponatinib up to day 70 (10 weeks of treatment), except for disease progression, intolerable toxicity, or withdrawal from study. Thereafter:~* Patients will receive Blinatumomab (minimum 2 cycles, up to a maximum of 5).~* Patients not achieving a CHR after 2 cycles of Blinatumomab will go off-study. After the 2 cycles of Blinatumomab patients aged 18-65 will be stratified for transplant allocation
Trial: NCT04722848
Drug: Chemotherapy + Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: patients aged 18-65 will receive chemotherapeutic scheme combined with Imatinib. Elderly patients will receive Imatinib plus mild chemotherapy.
Trial: NCT05659563
Drug: Giredestrant
RxNorm normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
Trial: NCT05659563
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen is a selective estrogen receptor (ER) modulator
Trial: NCT05964868
Drug: Liposomal Bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive post-operative liposomal bupivacaine (EXPAREL®) at the surgical site at the completion of their septorhinoplasty.
Trial: NCT05084651
Drug: Ganaplacide
RxNorm normalized name: Ganaplacide
DrugBank: Ganaplacide (DB16173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A/Period 1: 400 mg (4 x 100 mg tablets) at Hour 0 on Day 1 Treatment B/Period 2: 400 mg (4 x 100 mg tablets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
Trial: NCT05084651
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg (20 mL of 10 mg/mL oral solution) q.d. on Days 1 to 18
Trial: NCT06667622
Drug: sodium glycididazole
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium glycididazole is intravenously infused at a dose of 800mg at 60 min before radiotherapy and used on Mondays, Wednesdays and Fridays during radiotherapy.
Trial: NCT06685588
Drug: 5-FU (fluorouracil)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical 5-FU (fluorouracil) pretreatment prior to dovonex
Trial: NCT06685588
Drug: Calcipotriol
RxNorm normalized name: Calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol pre-treatment prior to PDT
Trial: NCT06683703
Drug: Utidelone combined with Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The initial dose was Utidelone 30mg/m2/d,D1-D5,Q3W+ Bevacizumab 15mg/kg/Q3w. If dose adjustment was required due to DLT events, Utidelone was reduced by up to one dose (to 25mg/m2/d), while the dose of Bevacizumab remained unchanged (15mg/kg).
Trial: NCT06683703
Drug: Utidelone
RxNorm normalized name: Utidelone
DrugBank: Utidelone (DB17575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utidelone injection, 30mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle
Trial: NCT06683703
Drug: Utidelone combined with Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the combination group, the dose of Utidelone was determined according to the safety run-in period, 30 mg/m2/d or 25mg/m2/d, D1-D5,Q3W; The dose of Bevacizumab was 15 mg/kg/3W.
Trial: NCT06683703
Drug: Utidelone combined with Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The dose of Utidelone was 30 mg/m2/d or 25mg/m2/d, D1-D5,Q3W; The dose of Bevacizumab was 15 mg/kg/3w.
Trial: NCT06683755
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV
Trial: NCT06683755
Drug: Relatlimab
RxNorm normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV